# GO	NS	enrichment	name	ratio_in_study	ratio_in_pop	p_uncorrected	depth	study_count	p_fdr_bh	study_items
hsa05014	XX	e	Amyotrophic lateral sclerosis	37/85	364/8061	6.441119878742875e-28	n.a	37	2.1255695599851486e-25	ALS2, ANG, ANXA11, ATXN2, BCL2L1, C9orf72, CASP1, CHCHD10, CHMP2B, DCTN1, ERBB4, FIG4, FUS, GLE1, HNRNPA1, HNRNPA2B1, KIF5A, MATR3, NEFH, OPTN, PFN1, PRPH, SETX, SIGMAR1, SLC1A2, SOD1, SPG11, SQSTM1, TARDBP, TBK1, TNF, TP53, TUBA4A, UBQLN2, UBQLN4, VAPB, VCP
hsa05022	XX	e	Pathways of neurodegeneration - multiple diseases	26/85	475/8061	1.0622290514315888e-12	n.a	26	1.7526779348621215e-10	ALS2, ATXN2, BCL2L1, C9orf72, CHMP2B, DCTN1, FIG4, FUS, GRIA3, KIF5A, NEFH, OPTN, PARK7, PRPH, PTGS2, SIGMAR1, SOD1, SPG11, SQSTM1, TARDBP, TBK1, TNF, TUBA4A, VAPB, VCP, WNT7A
hsa04217	XX	e	Necroptosis	8/85	159/8061	0.0002551025856009	n.a	8	0.0280612844161065	CASP1, CHMP2B, JAK3, PLA2G4A, SQSTM1, TNF, TRPM7, XIAP
hsa04210	XX	e	Apoptosis	7/85	136/8061	0.0005504898140084	n.a	7	0.0454154096556947	BCL2L1, CTSD, FOS, TNF, TP53, TUBA4A, XIAP
hsa04137	XX	e	Mitophagy - animal	5/85	68/8061	0.0007167343120219	n.a	5	0.0473044645934501	BCL2L1, OPTN, SQSTM1, TBK1, TP53
hsa05202	XX	e	Transcriptional misregulation in cancer	8/85	192/8061	0.0008983022479884	n.a	8	0.0494066236393623	BCL2L1, EWSR1, FUS, GRIA3, PDGFA, RXRA, TAF15, TP53
hsa05016	XX	e	Huntington disease	10/85	306/8061	0.0013439658670969	n.a	10	0.0633583908774263	CREBBP, DCTN1, GRIA3, KIF5A, PPARGC1A, SLC1A2, SOD1, SOD2, TP53, TUBA4A
hsa05222	XX	e	Small cell lung cancer	5/85	92/8061	0.0027762083254735	n.a	5	0.0858200378148346	BCL2L1, PTGS2, RXRA, TP53, XIAP
hsa05134	XX	e	Legionellosis	4/85	57/8061	0.0029736829719923	n.a	4	0.0858200378148346	CASP1, HSF1, TNF, VCP
hsa04014	XX	e	Ras signaling pathway	8/85	232/8061	0.0029809735617967	n.a	8	0.0858200378148346	BCL2L1, FGF6, LAT, PDGFA, PLA2G4A, SHC1, TBK1, TIAM1
hsa04657	XX	e	IL-17 signaling pathway	5/85	94/8061	0.003048392539018	n.a	5	0.0858200378148346	FOS, JUND, PTGS2, TBK1, TNF
hsa05135	XX	e	Yersinia infection	6/85	137/8061	0.0031462399908464	n.a	6	0.0858200378148346	ARHGEF28, CASP1, FOS, LAT, TBK1, TNF
hsa05418	XX	e	Fluid shear stress and atherosclerosis	6/85	139/8061	0.0033807893684631	n.a	6	0.0858200378148346	FOS, GSTP1, PDGFA, SQSTM1, TNF, TP53
hsa04064	XX	e	NF-kappa B signaling pathway	5/85	104/8061	0.0047056940774258	n.a	5	0.1109199318250387	BCL2L1, LAT, PTGS2, TNF, XIAP
hsa05223	XX	e	Non-small cell lung cancer	4/85	72/8061	0.0068742215255312	n.a	4	0.1379605736345991	JAK3, KIF5A, RXRA, TP53
hsa04630	XX	e	JAK-STAT signaling pathway	6/85	162/8061	0.0071070598539035	n.a	6	0.1379605736345991	BCL2L1, CNTF, CREBBP, GFAP, JAK3, PDGFA
hsa05161	XX	e	Hepatitis B	6/85	162/8061	0.0071070598539035	n.a	6	0.1379605736345991	CREBBP, FOS, JAK3, TBK1, TNF, TP53
hsa05214	XX	e	Glioma	4/85	75/8061	0.0079305426770157	n.a	4	0.1415201037739699	CAMK1G, PDGFA, SHC1, TP53
hsa05166	XX	e	Human T-cell leukemia virus 1 infection	7/85	219/8061	0.0081481271869861	n.a	7	0.1415201037739699	BCL2L1, CREBBP, FOS, JAK3, TNF, TP53, XIAP
hsa04380	XX	e	Osteoclast differentiation	5/85	127/8061	0.0107825775238629	n.a	5	0.1694405039464177	FOS, JUND, SQSTM1, TNF, TREM2
hsa04621	XX	e	NOD-like receptor signaling pathway	6/85	181/8061	0.011925858493406	n.a	6	0.1697652744251301	BCL2L1, CASP1, TBK1, TNF, TRPM7, XIAP
hsa04010	XX	e	MAPK signaling pathway	8/85	294/8061	0.0120254775084109	n.a	8	0.1697652744251301	ERBB4, FGF6, FOS, JUND, PDGFA, PLA2G4A, TNF, TP53
hsa05200	XX	e	Pathways in cancer	12/85	531/8061	0.0123465654127367	n.a	12	0.1697652744251301	BCL2L1, CREBBP, FGF6, FOS, GSTP1, JAK3, PDGFA, PTGS2, RXRA, TP53, WNT7A, XIAP
hsa04140	XX	e	Autophagy - animal	5/85	137/8061	0.014606166923976	n.a	5	0.1791407774959984	BCL2L1, C9orf72, CTSD, SQSTM1, TBK1
hsa05131	XX	e	Shigellosis	7/85	246/8061	0.0148148378501732	n.a	7	0.1791407774959984	BCL2L1, CASP1, PFN1, SQSTM1, TBK1, TNF, TP53
hsa05162	XX	e	Measles	5/85	139/8061	0.0154674122893507	n.a	5	0.1791407774959984	BCL2L1, FOS, JAK3, TBK1, TP53
hsa05132	XX	e	Salmonella infection	7/85	249/8061	0.0157426743860119	n.a	7	0.1791407774959984	CASP1, DCTN1, FOS, KIF5A, PFN1, TNF, TUBA4A
hsa04913	XX	e	Ovarian steroidogenesis	3/85	51/8061	0.0163782624282078	n.a	3	0.1801608867102861	LDLR, PLA2G4A, PTGS2
hsa05215	XX	e	Prostate cancer	4/85	97/8061	0.0190008862096773	n.a	4	0.1985351744717514	CREBBP, GSTP1, PDGFA, TP53
hsa05224	XX	e	Breast cancer	5/85	147/8061	0.0192518957063516	n.a	5	0.1985351744717514	FGF6, FOS, SHC1, TP53, WNT7A
hsa05226	XX	e	Gastric cancer	5/85	149/8061	0.0202853365004685	n.a	5	0.2028533650046856	FGF6, RXRA, SHC1, TP53, WNT7A
hsa05160	XX	e	Hepatitis C	5/85	157/8061	0.0247817831779803	n.a	5	0.2405290720215743	LDLR, RXRA, TBK1, TNF, TP53
hsa04659	XX	e	Th17 cell differentiation	4/85	107/8061	0.0261611220954107	n.a	4	0.2466620083281586	FOS, JAK3, LAT, RXRA
hsa05145	XX	e	Toxoplasmosis	4/85	112/8061	0.030274583571762	n.a	4	0.2775170160744859	BCL2L1, LDLR, TNF, XIAP
hsa05225	XX	e	Hepatocellular carcinoma	5/85	168/8061	0.0319469082666127	n.a	5	0.2849318845400594	BCL2L1, GSTP1, SHC1, TP53, WNT7A
hsa04664	XX	e	Fc epsilon RI signaling pathway	3/85	68/8061	0.034714340544528	n.a	3	0.3014666415709016	LAT, PLA2G4A, TNF
hsa04920	XX	e	Adipocytokine signaling pathway	3/85	69/8061	0.0360233719991793	n.a	3	0.3048131476853633	PPARGC1A, RXRA, TNF
hsa05218	XX	e	Melanoma	3/85	72/8061	0.040101542867091	n.a	3	0.3308377286535012	FGF6, PDGFA, TP53
hsa04215	XX	e	Apoptosis - multiple species	2/85	32/8061	0.0444341905298698	n.a	2	0.3521611111392632	BCL2L1, XIAP
hsa05133	XX	e	Pertussis	3/85	76/8061	0.0458876599363282	n.a	3	0.3521611111392632	CASP1, FOS, TNF
hsa05220	XX	e	Chronic myeloid leukemia	3/85	76/8061	0.0458876599363282	n.a	3	0.3521611111392632	BCL2L1, SHC1, TP53
hsa05140	XX	e	Leishmaniasis	3/85	77/8061	0.047395632725045	n.a	3	0.3554672454378376	FOS, PTGS2, TNF
hsa04721	XX	e	Synaptic vesicle cycle	3/85	78/8061	0.0489279174216458	n.a	3	0.358804727758736	SLC1A2, SLC6A1, UNC13A
hsa05167	XX	e	Kaposi sarcoma-associated herpesvirus infection	5/85	193/8061	0.052690192574024	n.a	5	0.3779948597701728	CREBBP, FOS, PTGS2, TBK1, TP53
hsa04146	XX	e	Peroxisome	3/85	82/8061	0.0552972561090889	n.a	3	0.388257330127646	DAO, SOD1, SOD2
hsa05216	XX	e	Thyroid cancer	2/85	37/8061	0.0576940423102373	n.a	2	0.3966465408828816	RXRA, TP53
hsa05169	XX	e	Epstein-Barr virus infection	5/85	202/8061	0.0617174034924222	n.a	5	0.4156478194387618	JAK3, TBK1, TNF, TP53, VIM
hsa05205	XX	e	Proteoglycans in cancer	5/85	205/8061	0.0649110868243896	n.a	5	0.4273724616535515	ERBB4, TIAM1, TNF, TP53, WNT7A
hsa05033	XX	e	Nicotine addiction	2/85	40/8061	0.0662267784746243	n.a	2	0.4273724616535515	GABRA1, GRIA3
hsa04211	XX	e	Longevity regulating pathway	3/85	89/8061	0.0673435394120747	n.a	3	0.4273724616535515	PPARGC1A, SOD2, TP53
hsa04015	XX	e	Rap1 signaling pathway	5/85	210/8061	0.0704382594554725	n.a	5	0.4385778418925647	FGF6, LAT, PDGFA, PFN1, TIAM1
hsa04658	XX	e	Th1 and Th2 cell differentiation	3/85	92/8061	0.0728444740443362	n.a	3	0.4451606747153878	FOS, JAK3, LAT
hsa04921	XX	e	Oxytocin signaling pathway	4/85	154/8061	0.0792287427922507	n.a	4	0.4703053339035249	CAMK1G, FOS, PLA2G4A, PTGS2
hsa04810	XX	e	Regulation of actin cytoskeleton	5/85	218/8061	0.0798093899957497	n.a	5	0.4703053339035249	FGF6, PDGFA, PFN1, TIAM1, TMSB4X
hsa05231	XX	e	Choline metabolism in cancer	3/85	98/8061	0.0844271387292713	n.a	3	0.4803613065630959	FOS, PDGFA, PLA2G4A
hsa03015	XX	e	mRNA surveillance pathway	3/85	98/8061	0.0844271387292713	n.a	3	0.4803613065630959	FUS, GLE1, TARDBP
hsa04625	XX	e	C-type lectin receptor signaling pathway	3/85	104/8061	0.0967463193266895	n.a	3	0.5122840085341541	CASP1, PTGS2, TNF
hsa04620	XX	e	Toll-like receptor signaling pathway	3/85	104/8061	0.0967463193266895	n.a	3	0.5122840085341541	FOS, TBK1, TNF
hsa04660	XX	e	T cell receptor signaling pathway	3/85	104/8061	0.0967463193266895	n.a	3	0.5122840085341541	FOS, LAT, TNF
hsa04979	XX	e	Cholesterol metabolism	2/85	50/8061	0.0973146226776723	n.a	2	0.5122840085341541	LDLR, VAPB
hsa04310	XX	e	Wnt signaling pathway	4/85	166/8061	0.0977996743565203	n.a	4	0.5122840085341541	CREBBP, TLE3, TP53, WNT7A
hsa04151	XX	e	PI3K-Akt signaling pathway	7/85	354/8061	0.1006039388991087	n.a	7	0.5128106924154773	BCL2L1, ERBB4, FGF6, JAK3, PDGFA, RXRA, TP53
hsa04928	XX	e	"""Parathyroid hormone synthesis, secretion and action"""	3/85	106/8061	0.101008166687897	n.a	3	0.5128106924154773	FOS, JUND, RXRA
hsa05164	XX	e	Influenza A	4/85	172/8061	0.1077892995071091	n.a	4	0.5389464975355459	CASP1, CREBBP, TBK1, TNF
hsa04668	XX	e	TNF signaling pathway	3/85	112/8061	0.1142344315577289	n.a	3	0.5626472002097095	FOS, PTGS2, TNF
hsa04724	XX	e	Glutamatergic synapse	3/85	114/8061	0.1187838478541332	n.a	3	0.5764510263509408	GRIA3, PLA2G4A, SLC1A2
hsa00480	XX	e	Glutathione metabolism	2/85	57/8061	0.1210589763332479	n.a	2	0.5789777128981424	GSR, GSTP1
hsa04330	XX	e	Notch signaling pathway	2/85	59/8061	0.1280856580998495	n.a	2	0.587020158169301	CREBBP, TLE3
hsa04370	XX	e	VEGF signaling pathway	2/85	59/8061	0.1280856580998495	n.a	2	0.587020158169301	PLA2G4A, PTGS2
hsa04935	XX	e	"""Growth hormone synthesis, secretion and action"""	3/85	119/8061	0.1304470514250812	n.a	3	0.587020158169301	CREBBP, FOS, SHC1
hsa04071	XX	e	Sphingolipid signaling pathway	3/85	119/8061	0.1304470514250812	n.a	3	0.587020158169301	CTSD, TNF, TP53
hsa04730	XX	e	Long-term depression	2/85	60/8061	0.1316348233470553	n.a	2	0.587020158169301	GRIA3, PLA2G4A
hsa00590	XX	e	Arachidonic acid metabolism	2/85	61/8061	0.1352067019145952	n.a	2	0.5871531547895735	PLA2G4A, PTGS2
hsa04919	XX	e	Thyroid hormone signaling pathway	3/85	121/8061	0.135223150800023	n.a	3	0.5871531547895735	CREBBP, RXRA, TP53
hsa04213	XX	e	Longevity regulating pathway - multiple species	2/85	62/8061	0.1388004359146704	n.a	2	0.5910925375414666	SOD1, SOD2
hsa04623	XX	e	Cytosolic DNA-sensing pathway	2/85	63/8061	0.1424151826284827	n.a	2	0.5910925375414666	CASP1, TBK1
hsa05217	XX	e	Basal cell carcinoma	2/85	63/8061	0.1424151826284827	n.a	2	0.5910925375414666	TP53, WNT7A
hsa05206	XX	e	MicroRNAs in cancer	6/85	310/8061	0.1432951606161131	n.a	6	0.5910925375414666	CREBBP, PDGFA, PTGS2, SHC1, TP53, VIM
hsa05130	XX	e	Pathogenic Escherichia coli infection	4/85	197/8061	0.153979985529109	n.a	4	0.627325866970444	CASP1, FOS, TNF, TUBA4A
hsa04650	XX	e	Natural killer cell mediated cytotoxicity	3/85	131/8061	0.1599713001824646	n.a	3	0.6308964909363671	LAT, SHC1, TNF
hsa04728	XX	e	Dopaminergic synapse	3/85	132/8061	0.1625198817891634	n.a	3	0.6308964909363671	FOS, GRIA3, KIF5A
hsa05165	XX	e	Human papillomavirus infection	6/85	331/8061	0.1635966683224671	n.a	6	0.6308964909363671	CREBBP, PTGS2, TBK1, TNF, TP53, WNT7A
hsa05031	XX	e	Amphetamine addiction	2/85	69/8061	0.1644995951882884	n.a	2	0.6308964909363671	FOS, GRIA3
hsa00982	XX	e	Drug metabolism - cytochrome P450	2/85	70/8061	0.1682390642496979	n.a	2	0.6308964909363671	FMO1, GSTP1
hsa04917	XX	e	Prolactin signaling pathway	2/85	70/8061	0.1682390642496979	n.a	2	0.6308964909363671	FOS, SHC1
hsa04622	XX	e	RIG-I-like receptor signaling pathway	2/85	70/8061	0.1682390642496979	n.a	2	0.6308964909363671	TBK1, TNF
hsa04520	XX	e	Adherens junction	2/85	71/8061	0.1719933249211019	n.a	2	0.6377280586962205	CREBBP, SNAI1
hsa04915	XX	e	Estrogen signaling pathway	3/85	137/8061	0.1754446908660389	n.a	3	0.6432971998421426	CTSD, FOS, SHC1
hsa04115	XX	e	p53 signaling pathway	2/85	73/8061	0.17954337160422	n.a	2	0.6510913475757429	BCL2L1, TP53
hsa05012	XX	e	Parkinson disease	5/85	249/8061	0.1905153671882355	n.a	5	0.6776067763594686	BCL2L1, KIF5A, PARK7, TP53, TUBA4A
hsa05212	XX	e	Pancreatic cancer	2/85	76/8061	0.1909619097013047	n.a	2	0.6776067763594686	BCL2L1, TP53
hsa04723	XX	e	Retrograde endocannabinoid signaling	3/85	148/8061	0.2048279835810024	n.a	3	0.7115077324392715	GABRA1, GRIA3, PTGS2
hsa04072	XX	e	Phospholipase D signaling pathway	3/85	148/8061	0.2048279835810024	n.a	3	0.7115077324392715	PDGFA, PLA2G4A, SHC1
hsa04932	XX	e	Non-alcoholic fatty liver disease	3/85	150/8061	0.2102923109618966	n.a	3	0.7228798189315196	FOS, RXRA, TNF
hsa05204	XX	e	Chemical carcinogenesis	2/85	83/8061	0.2179504536870047	n.a	2	0.7414809249145522	GSTP1, PTGS2
hsa04012	XX	e	ErbB signaling pathway	2/85	85/8061	0.2257283810179076	n.a	2	0.7562522812245883	ERBB4, SHC1
hsa04218	XX	e	Cellular senescence	3/85	156/8061	0.2268756843673764	n.a	3	0.7562522812245883	SQSTM1, TP53, TRPM7
hsa05210	XX	e	Colorectal cancer	2/85	86/8061	0.229625644063184	n.a	2	0.7577646254085073	FOS, TP53
hsa04540	XX	e	Gap junction	2/85	88/8061	0.2374340790304361	n.a	2	0.7658037317820721	PDGFA, TUBA4A
hsa04727	XX	e	GABAergic synapse	2/85	89/8061	0.2413442063798045	n.a	2	0.7658037317820721	GABRA1, SLC6A1
hsa05235	XX	e	PD-L1 expression and PD-1 checkpoint pathway in cancer	2/85	89/8061	0.2413442063798045	n.a	2	0.7658037317820721	FOS, LAT
hsa04976	XX	e	Bile secretion	2/85	90/8061	0.245257594322432	n.a	2	0.7708095821562149	LDLR, RXRA
hsa05323	XX	e	Rheumatoid arthritis	2/85	93/8061	0.2570124018015818	n.a	2	0.8001329490049246	FOS, TNF
hsa04350	XX	e	TGF-beta signaling pathway	2/85	94/8061	0.2609339609969957	n.a	2	0.8047495993365289	CREBBP, TNF
hsa04666	XX	e	Fc gamma R-mediated phagocytosis	2/85	97/8061	0.2727020915327134	n.a	2	0.8181062745981402	LAT, PLA2G4A
hsa04713	XX	e	Circadian entrainment	2/85	97/8061	0.2727020915327134	n.a	2	0.8181062745981402	FOS, GRIA3
hsa04925	XX	e	Aldosterone synthesis and secretion	2/85	98/8061	0.2766244863810581	n.a	2	0.8192936659150686	CAMK1G, LDLR
hsa04640	XX	e	Hematopoietic cell lineage	2/85	99/8061	0.2805460128739477	n.a	2	0.8192936659150686	CD7, TNF
hsa05170	XX	e	Human immunodeficiency virus 1 infection	4/85	212/8061	0.2873125851600037	n.a	4	0.8244395438993212	BCL2L1, FOS, TBK1, TNF
hsa04916	XX	e	Melanogenesis	2/85	101/8061	0.2883848164839123	n.a	2	0.8244395438993212	CREBBP, WNT7A
hsa04024	XX	e	cAMP signaling pathway	4/85	216/8061	0.2914784313507332	n.a	4	0.8244395438993212	CREBBP, FOS, GRIA3, TIAM1
hsa05142	XX	e	Chagas disease	2/85	102/8061	0.292301292837032	n.a	2	0.8244395438993212	FOS, TNF
hsa05163	XX	e	Human cytomegalovirus infection	4/85	225/8061	0.3019560399786064	n.a	4	0.8444533321435603	PTGS2, TBK1, TNF, TP53
hsa05171	XX	e	Coronavirus disease - COVID-19	4/85	232/8061	0.3110761452738302	n.a	4	0.8575576658062503	CASP1, FOS, TBK1, TNF
hsa04922	XX	e	Glucagon signaling pathway	2/85	107/8061	0.3118391512022728	n.a	2	0.8575576658062503	CREBBP, PPARGC1A
hsa04931	XX	e	Insulin resistance	2/85	108/8061	0.315735272771379	n.a	2	0.8610961984673974	PPARGC1A, TNF
hsa04020	XX	e	Calcium signaling pathway	4/85	240/8061	0.3224322195152475	n.a	4	0.8720639329193178	CAMK1G, ERBB4, FGF6, PDGFA
hsa04726	XX	e	Serotonergic synapse	2/85	113/8061	0.3351399004952676	n.a	2	0.8777473584399866	PLA2G4A, PTGS2
hsa04722	XX	e	Neurotrophin signaling pathway	2/85	119/8061	0.3582174285024945	n.a	2	0.906998740438812	SHC1, TP53
hsa04110	XX	e	Cell cycle	2/85	124/8061	0.3772341685928698	n.a	2	0.9290095196690076	CREBBP, TP53
hsa04142	XX	e	Lysosome	2/85	128/8061	0.3922847268470368	n.a	2	0.9449194150330084	CD68, CTSD
hsa04926	XX	e	Relaxin signaling pathway	2/85	129/8061	0.3960228730938767	n.a	2	0.9450114825911732	FOS, SHC1
hsa04068	XX	e	FoxO signaling pathway	2/85	131/8061	0.4034683139305812	n.a	2	0.9450114825911732	CREBBP, SOD2
hsa04141	XX	e	Protein processing in endoplasmic reticulum	3/85	171/8061	0.4293824716748347	n.a	3	0.963919834372078	UBQLN2, UBQLN4, VCP
hsa05152	XX	e	Tuberculosis	3/85	180/8061	0.4404275436064133	n.a	3	0.9809118879315162	CREBBP, CTSD, TNF
hsa03013	XX	e	RNA transport	3/85	186/8061	0.4486600792007442	n.a	3	0.9870521742416374	FUS, GLE1, TARDBP
hsa04062	XX	e	Chemokine signaling pathway	3/85	192/8061	0.4574987877036984	n.a	3	0.9996728799454708	JAK3, SHC1, TIAM1
hsa04510	XX	e	Focal adhesion	3/85	201/8061	0.4717383408661425	n.a	3	1.0	PDGFA, SHC1, XIAP
hsa05203	XX	e	Viral carcinogenesis	3/85	203/8061	0.4750433602178505	n.a	3	1.0	CREBBP, JAK3, TP53
hsa05020	XX	e	Prion disease	4/85	273/8061	0.5361404314860213	n.a	4	1.0	KIF5A, SOD1, TNF, TUBA4A
hsa05010	XX	e	Alzheimer disease	5/85	369/8061	0.5953243949916942	n.a	5	1.0	KIF5A, PTGS2, TNF, TUBA4A, WNT7A
hsa04910	XX	e	Insulin signaling pathway	2/85	137/8061	0.6566825954718195	n.a	2	1.0	PPARGC1A, SHC1
hsa04550	XX	e	Signaling pathways regulating pluripotency of stem cells	2/85	143/8061	0.6638508221661287	n.a	2	1.0	JAK3, WNT7A
hsa05017	XX	e	Spinocerebellar ataxia	2/85	143/8061	0.6638508221661287	n.a	2	1.0	ATXN2, GRIA3
hsa03040	XX	e	Spliceosome	2/85	151/8061	0.6740874803620196	n.a	2	1.0	FUS, HNRNPA1
hsa04150	XX	e	mTOR signaling pathway	2/85	154/8061	0.6780909923679596	n.a	2	1.0	TNF, WNT7A
hsa04934	XX	e	Cushing syndrome	2/85	155/8061	0.6794426803882428	n.a	2	1.0	LDLR, WNT7A
hsa04530	XX	e	Tight junction	2/85	169/8061	0.6990731194002343	n.a	2	1.0	TIAM1, TUBA4A
hsa04144	XX	e	Endocytosis	3/85	252/8061	0.7492790155251461	n.a	3	1.0	CHMP2B, KIF5A, LDLR
hsa05168	XX	p	Herpes simplex virus 1 infection	4/85	498/8061	0.8194163189911547	n.a	4	1.0	BCL2L1, TBK1, TNF, TP53
hsa04080	XX	p	Neuroactive ligand-receptor interaction	3/85	341/8061	1.0	n.a	3	1.0	GABRA1, GRIA3, PENK
hsa04060	XX	p	Cytokine-cytokine receptor interaction	3/85	295/8061	1.0	n.a	3	1.0	CNTF, TNF, TNFRSF21